PMID- 30172717
OWN - NLM
STAT- MEDLINE
DCOM- 20190726
LR  - 20231213
IS  - 1879-0542 (Electronic)
IS  - 0165-2478 (Print)
IS  - 0165-2478 (Linking)
VI  - 202
DP  - 2018 Oct
TI  - Identification of novel HIV-1-derived HLA-E-binding peptides.
PG  - 65-72
LID - S0165-2478(18)30209-8 [pii]
LID - 10.1016/j.imlet.2018.08.005 [doi]
AB  - Non-classical class Ib MHC-E molecule is becoming an increasingly interesting 
      component of the immune response. It is involved in both the adaptive and innate 
      immune responses to several chronic infections including HIV-1 and, under very 
      specific circumstances, likely mediated a unique vaccine protection of rhesus 
      macaques against pathogenic SIV challenge. Despite being recently in the 
      spotlight for HIV-1 vaccine development, to date there is only one reported human 
      leukocyte antigen (HLA)-E-binding peptide derived from HIV-1. In an effort to 
      help start understanding the possible functions of HLA-E in HIV-1 infection, we 
      determined novel HLA-E binding peptides derived from HIV-1 Gag, Pol and Vif 
      proteins. These peptides were identified in three independent assays, all 
      quantifying cell-surface stabilization of HLA-E*01:01 or HLA-E*01:03 molecules 
      upon peptide binding, which was detected by HLA-E-specific monoclonal antibody 
      and flow cytometry. Thus, following initial screen of over 400 HIV-1-derived 
      15-mer peptides, 4 novel 9-mer peptides PM9, RL9, RV9 and TP9 derived from 15-mer 
      binders specifically stabilized surface expression of HLA-E*01:03 on the cell 
      surface in two separate assays and 5 other binding candidates EI9, MD9, NR9, QF9 
      and YG9 gave a binding signal in only one of the two assays, but not both. 
      Overall, we have expanded the current knowledge of HIV-1-derived target peptides 
      stabilizing HLA-E cell-surface expression from 1 to 5, thus broadening inroads 
      for future studies. This is a small, but significant contribution towards 
      studying the fine mechanisms behind HLA-E actions and their possible use in 
      development of a new kind of vaccines.
CI  - Copyright (c) 2018 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Hannoun, Zara
AU  - Hannoun Z
AD  - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, 
      Oxford, United Kingdom.
FAU - Lin, Zhansong
AU  - Lin Z
AD  - Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
FAU - Brackenridge, Simon
AU  - Brackenridge S
AD  - NDM Research Building, Nuffield Department of Medicine, University of Oxford, 
      Oxford, United Kingdom.
FAU - Kuse, Nozomi
AU  - Kuse N
AD  - Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
FAU - Akahoshi, Tomohiro
AU  - Akahoshi T
AD  - Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
FAU - Borthwick, Nicola
AU  - Borthwick N
AD  - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, 
      Oxford, United Kingdom.
FAU - McMichael, Andrew
AU  - McMichael A
AD  - NDM Research Building, Nuffield Department of Medicine, University of Oxford, 
      Oxford, United Kingdom.
FAU - Murakoshi, Hayato
AU  - Murakoshi H
AD  - Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
FAU - Takiguchi, Masafumi
AU  - Takiguchi M
AD  - Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
FAU - Hanke, Tomas
AU  - Hanke T
AD  - The Jenner Institute, Nuffield Department of Medicine, University of Oxford, 
      Oxford, United Kingdom; International Research Center for Medical Sciences, 
      Kumamoto University, Kumamoto, Japan. Electronic address: 
      tomas.hanke@ndm.ox.ac.uk.
LA  - eng
GR  - G1001757/Medical Research Council/United Kingdom
GR  - MR/N023668/1/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180830
PL  - Netherlands
TA  - Immunol Lett
JT  - Immunology letters
JID - 7910006
RN  - 0 (AIDS Vaccines)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Peptides)
MH  - AIDS Vaccines/immunology
MH  - Antibodies, Monoclonal/immunology
MH  - Cell Line
MH  - HEK293 Cells
MH  - HIV Infections/immunology
MH  - HIV-1/*immunology
MH  - Histocompatibility Antigens Class I/*immunology
MH  - Humans
MH  - Peptides/*immunology
MH  - HLA-E Antigens
PMC - PMC6291738
OTO - NOTNLM
OT  - HIV-1
OT  - HLA-E bindning peptides
EDAT- 2018/09/03 06:00
MHDA- 2019/07/28 06:00
PMCR- 2018/10/01
CRDT- 2018/09/03 06:00
PHST- 2018/04/26 00:00 [received]
PHST- 2018/08/07 00:00 [revised]
PHST- 2018/08/23 00:00 [accepted]
PHST- 2018/09/03 06:00 [pubmed]
PHST- 2019/07/28 06:00 [medline]
PHST- 2018/09/03 06:00 [entrez]
PHST- 2018/10/01 00:00 [pmc-release]
AID - S0165-2478(18)30209-8 [pii]
AID - 10.1016/j.imlet.2018.08.005 [doi]
PST - ppublish
SO  - Immunol Lett. 2018 Oct;202:65-72. doi: 10.1016/j.imlet.2018.08.005. Epub 2018 Aug 
      30.